Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biological Chemistry

Enzyme inhibitors help reverse scars

Blocking the collagen cross-linking enzyme lysyl oxidase reduces scarring after injury has already occurred

by Stu Borman
August 29, 2016 | A version of this story appeared in Volume 94, Issue 34

[+]Enlarge
Credit: Iyer lab
This image shows cross-linked collagen (green) in cells from a patient with Dupuytren’s contracture, a hand deformity that involves scar tissue.
Micrograph shows cross-linked collagen in cells from a patient with Dupuytren’s contracture.
Credit: Iyer lab
This image shows cross-linked collagen (green) in cells from a patient with Dupuytren’s contracture, a hand deformity that involves scar tissue.

Few treatments are currently available to reduce scarring, which can be unsightly and can restrict movement. Researchers are now trying to develop a therapeutic agent that can reverse scarring of skin that was previously injured. Priyanka Toshniwal, a graduate student in Swaminathan Iyer’s group at the University of Western Australia, presented a poster on the work at the ACS national meeting last week. The UWA researchers—in collaboration with colleagues at the Fiona Wood Foundation, Royal Perth Hospital Burns Unit, and Pharmaxis, all in Australia—are studying compounds that inhibit the enzyme lysyl oxidase. When skin becomes damaged, lysyl oxidase catalyzes cross-linking of the protein collagen, forming scars that close the wound. Imaging and biochemical tests on human cells treated with lysyl oxidase inhibitors showed that the agents reduce collagen cross-linking, which could make skin look more normal. The researchers are now studying the efficacy of inhibitors in animal models and hope to start human trials of topical nanoformulations in a few years. Those who could benefit from such treatments include patients with burns, raised scars called keloids, and a hand deformity called Dupuytren’s contracture, the researchers say.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.